Credit Suisse Downgrades BIND Therapeutics To Neutral

Analysts at Credit Suisse downgraded BIND Therapeutics

from Outperform to Neutral. The price target for BIND Therapeutics has been lowered from $20 to $10. BIND Therapeutics shares have dropped 40.43% over the past 52 weeks, while the S&P 500 index has gained 16.21% in the same period. BIND Therapeutics' shares rose 0.90% to close at $6.72 yesterday.